Literature DB >> 30009817

Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.

Giovanni Barbara1, Madhusudan Grover2, Premysl Bercik3, Maura Corsetti4, Uday C Ghoshal5, Lena Ohman6, Mirjana Rajilić-Stojanović7.   

Abstract

BACKGROUND & AIMS: The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated by epidemiology studies conducted in diverse geographic and clinical settings. However, the available evidence has not been well summarized, and there is little guidance for diagnosis and treatment of PI-IBS. The ROME Foundation has produced a working team report to summarize the available evidence on the pathophysiology of PI-IBS and provide guidance for diagnosis and treatment, based on findings reported in the literature and clinical experience.
METHODS: The working team conducted an evidence-based review of publication databases for articles describing the clinical features (diagnosis), pathophysiology (intestinal sensorimotor function, microbiota, immune dysregulation, barrier dysfunction, enteroendocrine pathways, and genetics), and animal models of PI-IBS. We used a Delphi-based consensus system to create guidelines for management of PI-IBS and a developed treatment algorithm based on published findings and experiences of team members.
RESULTS: PI-IBS develops in about 10% of patients with infectious enteritis. Risk factors include female sex, younger age, psychological distress during or before acute gastroenteritis, and severity of the acute episode. The pathogenesis of PI-PBS appears to involve changes in the intestinal microbiome as well as epithelial, serotonergic, and immune system factors. However, these mechanisms are incompletely understood. There are no evidence-based, effective pharmacologic strategies for treatment of PI-IBS. We provide a consensus-based treatment algorithm, based on clinical presentation and potential disease mechanisms.
CONCLUSIONS: Based on a systematic review of the literature and team experience, we summarize the clinical features, pathophysiology (from animal models and human studies), and progression of PI-IBS. Based on these findings, we present an algorithm for diagnosis and treatment of PI-IBS based on team consensus. We also propose areas for future investigation.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barrier Function; Campylobacter; Gastrointestinal Infection; Microbiome; Serotonin

Mesh:

Year:  2018        PMID: 30009817      PMCID: PMC6309514          DOI: 10.1053/j.gastro.2018.07.011

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  93 in total

1.  Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation.

Authors:  Les Dethlefsen; David A Relman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-16       Impact factor: 11.205

2.  Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis.

Authors:  Mira M Wouters; Sander Van Wanrooy; Anh Nguyen; James Dooley; Javier Aguilera-Lizarraga; Winde Van Brabant; Josselyn E Garcia-Perez; Lukas Van Oudenhove; Marc Van Ranst; Jan Verhaegen; Adrian Liston; Guy Boeckxstaens
Journal:  Gut       Date:  2015-06-12       Impact factor: 23.059

Review 3.  Pediatric IBS: an overview on pathophysiology, diagnosis and treatment.

Authors:  Ashish Chogle; Stijn Mintjens; Miguel Saps
Journal:  Pediatr Ann       Date:  2014-04       Impact factor: 1.132

4.  The long-term stability of the human gut microbiota.

Authors:  Jeremiah J Faith; Janaki L Guruge; Mark Charbonneau; Sathish Subramanian; Henning Seedorf; Andrew L Goodman; Jose C Clemente; Rob Knight; Andrew C Heath; Rudolph L Leibel; Michael Rosenbaum; Jeffrey I Gordon
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

5.  Interstitial cells of cajal and inflammation-induced motor dysfunction in the mouse small intestine.

Authors:  T Der; P Bercik; G Donnelly; T Jackson; I Berezin; S M Collins; J D Huizinga
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients.

Authors:  K R Neal; J Hebden; R Spiller
Journal:  BMJ       Date:  1997-03-15

7.  Pathology of interstitial cells of Cajal in relation to inflammation revealed by ultrastructure but not immunohistochemistry.

Authors:  Xuan-Yu Wang; Irene Berezin; Hanne B Mikkelsen; Tara Der; Premysl Bercik; Stephen M Collins; Jan D Huizinga; Jan D Huizina
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

8.  Clinical and pathophysiological characteristics of acute-onset functional dyspepsia.

Authors:  Jan Tack; Ingrid Demedts; Geert Dehondt; Philip Caenepeel; Benjamin Fischler; Michele Zandecki; Jozef Janssens
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

Review 9.  Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome.

Authors:  M Thabane; D T Kottachchi; J K Marshall
Journal:  Aliment Pharmacol Ther       Date:  2007-08-15       Impact factor: 8.171

10.  Impaired acetylcholine release from the myenteric plexus of Trichinella-infected rats.

Authors:  S M Collins; P A Blennerhassett; M G Blennerhassett; D L Vermillion
Journal:  Am J Physiol       Date:  1989-12
View more
  42 in total

Review 1.  Antidepressants in inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Alexander C Ford; Douglas A Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-18       Impact factor: 46.802

Review 2.  Post-infection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition.

Authors:  Uday C Ghoshal; M Masudur Rahman
Journal:  Indian J Gastroenterol       Date:  2019-04

3.  The Brain-Gut-Microbiome Axis and Irritable Bowel Syndrome.

Authors:  Premysl Bercik
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-06

Review 4.  Is the Medium Still the Message? Culture-Independent Diagnosis of Gastrointestinal Infections.

Authors:  Neil Sood; Gary Carbell; Holly S Greenwald; Frank K Friedenberg
Journal:  Dig Dis Sci       Date:  2021-11-30       Impact factor: 3.199

Review 5.  Colonic diverticular disease.

Authors:  Antonio Tursi; Carmelo Scarpignato; Lisa L Strate; Angel Lanas; Wolfgang Kruis; Adi Lahat; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-03-26       Impact factor: 52.329

Review 6.  Sex- and Gender-Related Differences in Common Functional Gastroenterologic Disorders.

Authors:  Susrutha Puthanmadhom Narayanan; Bradley Anderson; Adil E Bharucha
Journal:  Mayo Clin Proc       Date:  2021-04       Impact factor: 7.616

Review 7.  The enteric nervous system in gastrointestinal disease etiology.

Authors:  Amy Marie Holland; Ana Carina Bon-Frauches; Daniel Keszthelyi; Veerle Melotte; Werend Boesmans
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

8.  Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms.

Authors:  Patrick Denis Browne; Frederik Cold; Andreas Munk Petersen; Sofie Ingdam Halkjær; Alice Højer Christensen; Stig Günther; Lars Hestbjerg Hansen
Journal:  Gut Microbes       Date:  2021 Jan-Dec

9.  Clostridium butyricum relieve the visceral hypersensitivity in mice induced by Citrobacter rodentium infection with chronic stress.

Authors:  Tengfei Wang; Lixiang Li; Shiyang Li; Hongyu Zhao; Junyan Qu; Yanan Xia; Yanqing Li
Journal:  PeerJ       Date:  2021-06-21       Impact factor: 2.984

10.  Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study.

Authors:  Daniele Noviello; Andrea Costantino; Antonio Muscatello; Alessandra Bandera; Dario Consonni; Maurizio Vecchi; Guido Basilisco
Journal:  Neurogastroenterol Motil       Date:  2021-06-01       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.